Literature DB >> 25952647

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.

Shintaro Takeuchi1, Muhammad Baghdadi2, Takahiro Tsuchikawa3, Haruka Wada2, Toru Nakamura3, Hirotake Abe1, Sayaka Nakanishi2, Yuu Usui2, Kohtaro Higuchi2, Mizuna Takahashi3, Kazuho Inoko3, Syoki Sato3, Hironobu Takano3, Toshiaki Shichinohe3, Ken-ichiro Seino4, Satoshi Hirano5.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic malignancies. PDAC builds a tumor microenvironment that plays critical roles in tumor progression and metastasis. However, the relationship between chemotherapy and modulation of PDAC-induced tumor microenvironment remains poorly understood. In this study, we report a role of chemotherapy-derived inflammatory response in the enrichment of PDAC microenvironment with immunosuppressive myeloid cells. Granulocyte macrophage colony-stimulating factor (GM-CSF) is a major cytokine associated with oncogenic KRAS in PDAC cells. GM-CSF production was significantly enhanced in various PDAC cell lines or PDAC tumor tissues from patients after treatment with chemotherapy, which induced the differentiation of monocytes into myeloid-derived suppressor cells (MDSC). Furthermore, blockade of GM-CSF with monoclonal antibodies helped to restore T-cell proliferation when cocultured with monocytes stimulated with tumor supernatants. GM-CSF expression was also observed in primary tumors and correlated with poor prognosis in PDAC patients. Together, these results describe a role of GM-CSF in the modification of chemotherapy-treated PDAC microenvironment and suggest that the targeting of GM-CSF may benefit PDAC patients' refractory to current anticancer regimens by defeating MDSC-mediated immune escape. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25952647     DOI: 10.1158/0008-5472.CAN-14-2921

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.

Authors:  Qiuyan Liu; Ha Zhu; Chaoxiong Zhang; Taoyong Chen; Xuetao Cao
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

2.  Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Authors:  Tulasigeri M Totiger; Supriya Srinivasan; Venkatakrishna R Jala; Purushottam Lamichhane; Austin R Dosch; Alexander A Gaidarski; Chandrashekhar Joshi; Shobith Rangappa; Jason Castellanos; Praveen Kumar Vemula; Xi Chen; Deukwoo Kwon; Nilesh Kashikar; Michael VanSaun; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Ther       Date:  2018-11-07       Impact factor: 6.261

Review 3.  Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems.

Authors:  Martin C Whittle; Sunil R Hingorani
Journal:  Cancer J       Date:  2017 Nov/Dec       Impact factor: 3.360

4.  Black raspberries suppress pancreatic cancer through modulation of NKp46+, CD8+, and CD11b+ immune cells.

Authors:  Pan Pan; Zheng Zhu; Kiyoko Oshima; Mohammed Aldakkak; Susan Tsai; Yi-Wen Huang; Wenjuan Dong; Jianying Zhang; Chien-Wei Lin; Youwei Wang; Martha Yearsley; Jianhua Yu; Li-Shu Wang
Journal:  Food Front       Date:  2020-03-26

5.  Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer.

Authors:  Supriya Srinivasan; Tulasigeri Totiger; Chanjuan Shi; Jason Castellanos; Purushottam Lamichhane; Austin R Dosch; Fanuel Messaggio; Nilesh Kashikar; Kumaraswamy Honnenahally; Yuguang Ban; Nipun B Merchant; Michael VanSaun; Nagaraj S Nagathihalli
Journal:  Cancer Res       Date:  2018-09-19       Impact factor: 12.701

Review 6.  CAR T-cell therapy for pancreatic cancer.

Authors:  Carl J DeSelm; Zachary E Tano; Anna M Varghese; Prasad S Adusumilli
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 3.454

7.  Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6Chigh Myeloid Cells.

Authors:  Caijun Wu; Xiaobin Tan; Xiaoling Hu; Mingqian Zhou; Jun Yan; Chuanlin Ding
Journal:  J Immunol       Date:  2019-11-27       Impact factor: 5.422

Review 8.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

Review 9.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

Review 10.  Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer.

Authors:  Christopher J Halbrook; Marina Pasca di Magliano; Costas A Lyssiotis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-15       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.